Greenwich Lifesciences Stock Alpha and Beta Analysis
| GLSI Stock | USD 11.78 0.07 0.60% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Greenwich Lifesciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Greenwich Lifesciences over a specified time horizon. Remember, high Greenwich Lifesciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Greenwich Lifesciences' market risk premium analysis include:
Beta 1.16 | Alpha (0.07) | Risk 3.01 | Sharpe Ratio (0.04) | Expected Return (0.11) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Greenwich |
Greenwich Lifesciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Greenwich Lifesciences market risk premium is the additional return an investor will receive from holding Greenwich Lifesciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Greenwich Lifesciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Greenwich Lifesciences' performance over market.| α | -0.07 | β | 1.16 |
Greenwich Lifesciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Greenwich Lifesciences' Buy-and-hold return. Our buy-and-hold chart shows how Greenwich Lifesciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Greenwich Lifesciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Greenwich Lifesciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Greenwich Lifesciences shares will generate the highest return on investment. By understating and applying Greenwich Lifesciences stock market price indicators, traders can identify Greenwich Lifesciences position entry and exit signals to maximize returns.
Greenwich Lifesciences Return and Market Media
The median price of Greenwich Lifesciences for the period between Sat, Dec 14, 2024 and Fri, Mar 14, 2025 is 12.4 with a coefficient of variation of 5.37. The daily time series for the period is distributed with a sample standard deviation of 0.67, arithmetic mean of 12.48, and mean deviation of 0.56. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Mcwilliams David of 61984 shares of Greenwich Lifesciences at 12.16 subject to Rule 16b-3 | 12/24/2024 |
2 | Acquisition by Snehal Patel of 3200 shares of Greenwich Lifesciences at 11.12 subject to Rule 16b-3 | 12/30/2024 |
3 | Acquisition by Snehal Patel of 2500 shares of Greenwich Lifesciences at 12.51 subject to Rule 16b-3 | 01/10/2025 |
4 | Greenwich LifeSciences Partners with Unicancer Expanding Flamingo-01 into France | 01/13/2025 |
5 | Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01 | 01/14/2025 |
6 | Greenwich LifeSciences Provides Update on Commercial Manufacturing | 01/22/2025 |
7 | Bullish Greenwich LifeSciences Insiders Loaded Up On US3.39m Of Stock | 01/23/2025 |
8 | Greenwich LifeSciences Expands Phase III Breast Cancer Trial Across Poland - StockTitan | 01/27/2025 |
9 | Major Breakthrough Cancer Prevention Trial Goes Europe-Wide as Top Medical Centers Join Forces - StockTitan | 01/29/2025 |
10 | Greenwich LifeSciences Provides Update on Open Label HLA Data fr | 02/10/2025 |
11 | Acquisition by Snehal Patel of 2000 shares of Greenwich Lifesciences at 9.72 subject to Rule 16b-3 | 02/25/2025 |
12 | Learn to Evaluate using the Charts - Stock Traders Daily | 02/27/2025 |
13 | Acquisition by Snehal Patel of 12000 shares of Greenwich Lifesciences at 8.33 subject to Rule 16b-3 | 03/06/2025 |
14 | Trading With Integrated Risk Controls - Stock Traders Daily | 03/10/2025 |
About Greenwich Lifesciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Greenwich or other stocks. Alpha measures the amount that position in Greenwich Lifesciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Greenwich Lifesciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Greenwich Lifesciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Greenwich Lifesciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Greenwich Lifesciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Greenwich Lifesciences. Please utilize our Beneish M Score to check the likelihood of Greenwich Lifesciences' management manipulating its earnings.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 27th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Greenwich Lifesciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Greenwich Lifesciences Backtesting, Greenwich Lifesciences Valuation, Greenwich Lifesciences Correlation, Greenwich Lifesciences Hype Analysis, Greenwich Lifesciences Volatility, Greenwich Lifesciences History and analyze Greenwich Lifesciences Performance. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Greenwich Lifesciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.